antiviral
As cases rise, WHO says monkeypox risk is “moderate”
Phil Taylor
antiviral, monkeypox, public health, Smallpox, vaccines, World Health Organisation
0 Comment
Monkeypox cases are rising. Should we be worried?
Phil Taylor
antiviral, Bavarian Nordic, infectious disease, monkeypox, SIGA technologies, Smallpox, vaccine, World Health Organisation
0 Comment
News/ News/ Sales and Marketing
Merck makes $3.2bn from COVID-19 drug Lagevrio in Q1
Phil Taylor
antiviral, coronavirus, COVID-19, Financial, Gardasil, Keytruda, Lagevrio, Merck & Co
0 Comment
Pfizer bulks up in RSV with $525m takeover of ReViral
Phil Taylor
antiviral, infectious disease, M&A, paediatrics, Pfizer, respiratory syncytial virus, ReViral
0 Comment
Synairgen slumps as inhaled COVID drug fails pivotal test
Phil Taylor
antiviral, coronavirus, COVID-19, interferon, respiratory, Synairgen
0 Comment
News/ News/ Sales and Marketing
FDA clears Gilead’s Veklury for COVID outpatients
Phil Taylor
antiviral, coronavirus, COVID-19, fda, Gilead Sciences, NIH, Veklury
0 Comment
After trial win, Novartis nabs COVID drug from Molecular Partners
Phil Taylor
antiviral, coronavirus, COVID-19, DARPin, Molecular Partners, Novartis, partnering
0 Comment
Update: Pfizer pips Merck to first oral COVID antiviral okay in US
Phil Taylor
antiviral, coronavirus, COVID-19, fda, Merck & Co, molnupiravir, Paxlovid, Pfizer
0 Comment